Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2020 Mar 20

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Medica 2020 Mar 20

DOI: 10.23736/S0026-4806.20.06463-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Study on the mechanism of curcumin to reduce the inflammatory response of temporal lobe in Alzheimer's disease by regulating miR-146a

Jingfeng GONG 1 , Derong SUN 2

1 Department of Neurology (I), The Fourth Hospital of Daqing, Daqing, P.R. China; 2 General Department, North Banch of The Fourth Affiliated Hospital of Harbin Medical University, Harbin, P.R. China


PDF


BACKGROUND: To explore the potential mechanism of curcumin in the treatment of Alzheimer's disease and clarify the role of miR-146a in the neuroinflammatory response to Alzheimer's disease.
METHODS: Clinical case study: 20 AD patients and 20 age-gender matched non-inflammatory and non-dementia patients in the department of neurology of our hospital were included, peripheral venous blood and cerebrospinal fluid were collected, and mir-146a levels in peripheral blood and cerebrospinal fluid were detected by real-time fluorescence quantitative PCR. Animal experimental study group: There were 3 groups, including APP/PS1 mice control group, APP/PS1 mice low-dose curcumin treatment group, and C57BL/6J mice wild-type (WT) control group, with 10 mice in each group. mir-146a levels in mice brain tissue were detected by quantitative real-time PCR. Aβ, APP, complement factor H (CFH) and M1 microglia labeled IL-1 β and iNOS in temporal lobe tissues of mice were detected by using Westernblot method.
RESULTS: The plasma miRNA-146a level in AD group was 39.10 ±12.97 fmol/L, and that in control group was 60.54 ±13.16 fmol/L. The plasma miRNA-146a level in AD group was significantly lower than that in control group. The level of miRNA-146a in cerebrospinal fluid of AD group (25.16 ± 5.16 fmol/L) was significantly higher than that of control group (11.35 ±3.58 fmol/L). After treatment with low dose curcumin, the level of miRNA-146a in APP/PS1 mice decreased significantly, and the expression of A β and APP/PS1 in temporal lobe of mice detected by Western blot decreased significantly, the levels of IL-1 β and iNOS protein decreased significantly, and the protein of CFH increased signifanctly.
CONCLUSIONS: miRNA-146a can be used as one of the potential biomarkers of AD. Low dose curcumin can significantly reduce the level of neuropro-inflammatory miR-146A, up-regulate the expression of CFH protein, inhibit the phenotype of M1 microglia, and play a role in the treatment of AD by promoting the phagocytosis and clearance mechanism of A β.


KEY WORDS: Curcumin; Alzheimer's disease; miRNA-146a; M1 microglia

inizio pagina